REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

NCT06315010 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
Brain Metastases
ROS1 Gene Rearrangement

Interventions

DRUG: Repotrectinib

Sponsor

MedSIR

Collaborators

[object Object]